ReviewNature reviews. Drug discovery2013
New avenues for anti-epileptic drug discovery and development.
Review in Nature reviews. Drug discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
248 citing papers in PubMed, 4 syntheses or guidelines pooled it, 666 citations in OpenAlex.
- Pooled it
- Progress in TLE treatment from 2003 to 2023: scientific measurement and visual analysis based on CiteSpace.Frontiers in neurology · 2023Pooled it
- The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review.Acta neurologica Belgica · 2022Pooled it
- Ketogenic diet for the treatment of pediatric epilepsy: review and meta-analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Pooled it
- Impact of two ketogenic diet types in refractory childhood epilepsy.Pediatric research · 2023Trial
- PD-1 Is an Immune-Inflammatory Potential Biomarker in Cerebrospinal Fluid and Serum of Intractable Epilepsy.BioMed research international · 2021Trial
- Narrative Review: Efficacy, Safety, and Tolerability of Newer Third-Generation Antiseizure Medications for Focal Epilepsy: A New Benchmark in Treatment Outcomes?Neurology and therapy · 2026Review
- Advancing the Paradigm of Temporal Lobe Epilepsy as a Network Disease: The Promise of Biomarkers and Targeted Disease Modification.International journal of molecular sciences · 2026Review
- Pharmacokinetics, Safety, and Dosing of Antiseizure Medications in Patients with Renal or Hepatic Impairment.Clinical pharmacokinetics · 2026Review
- Effects of Clopidogrel on the Anticonvulsant Efficacy of Valproic Acid and Levetiracetam in a PTZ-Induced Seizure Model.International journal of molecular sciences · 2026Article
- Integrative single-cell and spatial transcriptomics combined with machine learning to discover complement-associated biomarkers in temporal lobe epilepsy with hippocampal sclerosis.Functional & integrative genomics · 2026Article
- AAV-mediated GPR173 gene therapy attenuates long-term refractory epilepsy by enhancing synaptic GABAActa pharmacologica Sinica · 2026Article
- Article
- A stage-resolved neuron-glia transcriptional atlas reveals a glial inflammatory pivot in epilepsy.Acta neuropathologica communications · 2026Article
- Qualitative EEG morphology predicts early Antiseizure medication response in newly diagnosed epilepsy: A prospective cohort study.Epilepsy & behavior reports · 2026Article
- Article
- Iron single-atom nanozyme-mediated laser interstitial thermal therapy and anti-inflammatory effect for epilepsy.Materials today. Bio · 2026Article
- Hippocampal Oligodendrocytes Regulate Mossy Fiber Development Involved in Epileptic Responses.Neuroscience bulletin · 2026Article
- Targeting Hsp90 with cemdomespib reduces seizure burden and alters disease course in preclinical epilepsy models.Epilepsia · 2026Article
- Health-related quality of life and associated factors among patients living with epilepsy of Mekelle City Hospitals, Northern Ethiopia: a multicenter observational study.Health and quality of life outcomes · 2026Observational
188 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the introduction of over 15 third-generation anti-epileptic drugs, current medications fail to control seizures in 20-30% of patients. However, our understanding of the mechanisms mediating the development of epilepsy and the causes of drug resistance has grown substantially over the past decade, providing opportunities for the discovery and development of more efficacious anti-epileptic and anti-epileptogenic drugs. In this Review we discuss how previous preclinical models and clinical trial designs may have hampered the discovery of better treatments. We propose that future anti-epileptic drug development may be improved through a new joint endeavour between academia and the industry, through the identification and application of tools for new target-driven approaches, and through comparative preclinical proof-of-concept studies and innovative clinical trials designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.